Lund­beck part­ners with Van­der­bilt on new schiz­o­phre­nia drug; Pere­grine of­fi­cial­ly re­named Avid BioSer­vices in pur­suit of CD­MO iden­ti­ty

→ Lund­beck is part­ner­ing with re­searchers at Van­der­bilt Uni­ver­si­ty on a pre­clin­i­cal pro­gram for schiz­o­phre­nia. In­ves­ti­ga­tors at the uni­ver­si­ty have been study­ing a new …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER